Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: C1 esterase inhibitor (human)
Trade Name: Cinryze
Date Designated: 07/16/2004
Orphan Designation: Treatment of angioedema
Orphan Designation Status: Designated/Approved
Takeda Development Center Americas, Inc.
500 Kendall Street
Cambridge, Massachusetts 02142
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: C1 esterase inhibitor (human)
Trade Name: Cinryze
Marketing Approval Date: 10/10/2008
Approved Labeled Indication: Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE)
Exclusivity End Date: 10/10/2015 
Exclusivity Protected Indication* :  
2 Generic Name: C1 esterase inhibitor (human)
Trade Name: Cinryze
Marketing Approval Date: 06/20/2018
Approved Labeled Indication: CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).
Exclusivity End Date: 06/20/2025 
Exclusivity Protected Indication* :  CINRYZE (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in pediatric patients ages 6-11 with Hereditary Angioedema (HAE).
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-